PB2326: SAFE AND EFFECTIVE PROPHYLAXIS WITH PLASMA-DERIVED FACTOR X CONCENTRATE IN AN ELDERLY PATIENT WITH HEREDITARY FACTOR X DEFICIENCY

Abstract

Background: Coagulation factor X, human is a plasma-derived factor X concentrate indicated to treat and prevent bleeding in individuals with hereditary factor X deficiency (HFXD). The ages of patients in whom data was collected in the initial registration trials and post-marketing studies ranged from 0-58 years. To date, there have been no reports on treatment of elderly (>65 years) patients with plasma-derived factor X (pdFX) concentrate. Aims: To report the experience with pdFX concentrate in the prophylactic treatment of HFXD in a patient >65 years. Methods: Data was collected on a 71-year-old female with HFXD receiving prophylactic treatment with pdFX. Results: Although suspected to have some type of bleeding disorder since age 2, this individual was not diagnosed with HFXD until age 20. Initial treatment included fresh frozen plasma on-demand for acute bleeding episodes. Subsequent treatment included three-factor prothrombin complex concentrate (PCC), starting in the 1990s. Prophylactic treatment was started at age 57 after she developed a spontaneous subdural hematoma. She was transitioned from PCC to pdFX prophylaxis in November 2019 to more directly address her factor X deficiency and to avoid increasing other clotting factor levels above the normal range. She is currently receiving pdFX 21 units/kg weekly, which has been well tolerated and she has experienced no bleeding issues since starting this therapy. Summary/Conclusion: This is the first reported experience of prophylactic treatment of an elderly patient with pdFX. Additional details of this case including laboratory data and updates from her recent clinic visit(s) will be presented. The data supports the successful prophylactic treatment of elderly patients and the need to continue to collect data in this population of patients with this rare bleeding disorder.